| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2559.2011.04017.X |
| P698 | PubMed publication ID | 22092394 |
| P2093 | author name string | Stephen Lee | |
| Michael Platten | |||
| Marian Priyanthi Kumarasinghe | |||
| Willem Bastiaan de Boer | |||
| Soraya Fermoyle | |||
| P433 | issue | 5 | |
| P921 | main subject | heterogeneity | Q928498 |
| P304 | page(s) | 832-840 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Histopathology | Q1524040 |
| P1476 | title | Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections | |
| P478 | volume | 59 |
| Q36910400 | Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma |
| Q44885327 | Are biopsy specimens predictive of HER2 status in gastric cancer patients? |
| Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
| Q35831069 | Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections |
| Q91865170 | Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer |
| Q87944884 | Clinicopathological features and endoscopic findings of HER2-positive gastric cancer |
| Q54348234 | Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. |
| Q36897947 | Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population |
| Q28538710 | EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model? |
| Q41812451 | Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer |
| Q64103596 | Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times |
| Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
| Q36739953 | HER2 Expression in Gastric Adenocarcinoma-a Study in a Tertiary Care Centre in South India |
| Q89879114 | HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies |
| Q33925610 | HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patients |
| Q26780318 | HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q54340137 | HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). |
| Q26741253 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice |
| Q34324291 | HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. |
| Q50878559 | HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. |
| Q54312070 | HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? |
| Q50993984 | HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. |
| Q37468290 | HER2-positive gastric cancer |
| Q60915393 | HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma |
| Q33917507 | HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development |
| Q36615782 | Her2/neu testing in gastric cancer: evaluating the risk of sampling errors |
| Q89795555 | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives |
| Q89303203 | Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples |
| Q36546068 | Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens |
| Q47764668 | Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis |
| Q43551349 | Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma |
| Q51232753 | Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. |
| Q91456017 | Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer |
| Q55261916 | Prognostic implications of HER2 heterogeneity in gastric cancer. |
| Q35525379 | Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule |
| Q36801203 | Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization |
| Q36613291 | The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples |
| Q34855628 | The effect of Helicobacter pylori CagA on the HER-2 copy number and expression in gastric cancer. |
| Q44522454 | Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice |
| Q33733858 | Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer |
Search more.